Patient leaflet in accordance with the Pharmacists' Regulations (Preparations) - 1986

This medicine is dispensed with a doctor's prescription only

Livtencity
Film-coated tablets

Active ingredient:
maribavir 200 mg

Inactive ingredients and allergens in this medicine: see section 2 under 'Important information about some of this medicine's ingredients', and section 6 'Additional information'.

Read the entire leaflet carefully before you start using this medicine. This leaflet contains concise information about this medicine. If you have any further questions, consult your doctor or pharmacist.

This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if it seems to you that their medical condition is similar to yours.

1. What is this medicine intended for?

Livtencity is indicated for the treatment of adults and pediatric patients (12 years of age and older weighing at least 35 kg) with post-transplant cytomegalovirus (CMV) infection/disease, that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir or foscarnet.

Therapeutic group: Antivirals
Livtencity is an antiviral medicine against the CMV virus.

2. Before using this medicine

Do not use this medicine if:

- You are sensitive (allergic) to the active ingredient or to any of the other ingredients in this medicine (see section 6).

Special warnings about using this medicine
Before using Livtencity, tell your doctor if:

- You are taking anticonvulsants
- You are using ganciclovir or valganciclovir. Concomitant use with Livtencity is not recommended. See section 'Interactions with other medicines'.

Additional warnings

- Treatment failure due to resistance may occur during and after treatment with Livtencity. Disease relapse after treatment discontinuation may occur within 4-8 weeks after

treatment discontinuation. In case of lack of response to treatment or disease relapse, your doctor should monitor CMV levels and check for viral resistance to the medicine.
- Concomitant use of Livtencity and certain medicines may cause drug interactions which may lead to reduced efficacy of Livtencity or side effects resulting from the concomitant medicines. See section 'Interactions with other medicines'. Do not start any new medicine without informing your doctor. Your doctor will check whether taking Livtencity with other medicines is safe.
- Livtencity may increase the levels of immunosuppressants that are CYP3A4 and/or P-gp substrates, such as everolimus, sirolimus, cyclosporine and tacrolimus. Minimal changes in the concentration of immunosuppressants may lead to serious side effects. See section 'Interactions with other medicines'. Your doctor should frequently monitor blood levels of immunosuppressants, especially at the beginning and end of treatment, to adjust the dosage of immunosuppressants.

Children and adolescents
There is no information about the safety and efficacy of using Livtencity in children below 12 years of age.
The recommended dosage for children aged 12 years and older weighing at least 35 kg is identical to the adult dosage.

Interactions with other medicines
If you are taking or have recently taken other medicines, including nonprescription medicines and dietary supplements, tell your doctor or pharmacist. Particularly if you are taking:
ganciclovir or valganciclovir (antiviral medicines). Concomitant intake of Livtencity may reduce their efficacy, and therefore, the combination is not recommended.
<u>The following medicines may decrease the blood concentration of Livtencity and reduce its efficacy:</u>
- carbamazepine, phenobarbital, phenytoin – medicines also used against seizures – see also section 3 'Dosage adjustment when co-administered with anticonvulsants'
- rifabutin, rifampin – medicines used to treat infections
- hypericum perforatum (St. John’s wort) – for treatment of depression

<u>The blood concentration of the following medicines may increase upon concomitant use with Livtencity:</u>
- digoxin – a medicine used to treat cardiac disorders
- rosuvastatin – for treatment of blood lipids
- cyclosporine, everolimus, sirolimus, tacrolimus – immunosuppressants. See also 'Additional warnings'.

Using this medicine and food
Take the medicine orally, with or without food.

Pregnancy, breastfeeding, and fertility
If you are pregnant, plan to become pregnant, plan to breastfeed or are breastfeeding, do not use this medicine without consulting your doctor prior to starting treatment.

There is no sufficient information to establish the safety of using this medicine during pregnancy.
It is not known if Livtencity or its metabolites are secreted into breast milk, if there is any effect on milk production or on the breastfed baby. Consult your doctor about the best way to feed your baby during treatment with Livtencity.

Important information about some of this medicine's ingredients
Livtencity contains less than 1 mmol (23 mg) sodium per dose, therefore it is considered essentially 'sodium free'.

3. How to use this medicine?

Always use this medicine according to your doctor's instructions. Check with your doctor or pharmacist if you are not sure about your dose or about how to take this medicine. Only your doctor will determine your dose and how you should take this medicine.

The recommended dosage is usually:
400 mg (two 200 mg tablets) twice daily, with or without food.

Dosage adjustment when co-administered with anticonvulsants:
If you are also taking carbamazepine, the recommended dosage of Livtencity is 800 mg (four 200 mg tablets) twice daily.
If you are also taking phenytoin or phenobarbital, the recommended dosage of Livtencity is 1200 mg (six 200 mg tablets) twice daily.

Do not exceed the recommended dose.

Method of administration
Swallow the tablets whole. If you are not able to swallow tablets whole, you can break apart (disperse) the tablets in drinking water **or** crush the tablets and mix with drinking water and take by mouth. The tablet will not be completely dispersed in the mixture.

- **Do not mix** the tablets with any liquid other than water.
- Livtencity tablets that have been dispersed in water can be given through the nose (nasogastric (NG)) or mouth (orogastric (OG)) tube (size 10 Fr or larger).
- The mixture can be prepared ahead of time and stored below 25°C for up to 8 hours.

Instructions for preparing dispersed or crushed tablets and taking by mouth
Prepare:

- a clean glass
- drinking water

Step 1: Prepare a clean, flat work surface and place all the necessary supplies on it.
Step 2: Wash and dry your hands well.
Step 3: Prepare the prescribed number of Livtencity tablets needed to prepare the dose.
Step 4: Place the tablets in the glass.
Note: You can crush the tablets with a spoon before adding water.
Step 5: Add water at the volume needed for your prescribed dose.

Number of tablets	Volume of drinking water (ml)
2	30
4	60
6	90

Step 6: Swirl the glass contents gently to disperse the tablets in the water and swallow the mixture right away before sedimentation of the particles. The mixture has a bitter taste.
Step 7: Add 15 ml of water and swallow the contents.

Repeat Step 7. Check that no residues of the tablet are left in the glass. Repeat Step 7 until no medicine residues remain.

Instructions for preparing and giving the tablets through a nasogastric (NG) or orogastric (OG) tube

Prepare:

- a 50 ml or 60 ml syringe
- drinking water

Step 1: Remove the cap (if capped) and plunger out of a 50 ml or 60 ml syringe. Add 2 tablets into the syringe body and place the plunger back in the syringe.
Note: Only 2 tablets can be given through a feeding tube at a time.
Step 2: Withdraw 30 ml of drinking water into the syringe.
Step 3: Hold the syringe with the tip pointing upward. Pull the plunger back to draw air into the syringe. Place the cap back on the syringe (if there is a cap). Shake the syringe well for about 30 to 45 seconds or until the tablets are completely dispersed. Be careful not to spill the contents of the syringe.
Step 4: Remove the cap (if capped) from the syringe again, attach the syringe to the feeding tube and give the mixture right away before sedimentation of the particles.
Step 5: Withdraw 15 ml of water into the same syringe and flush through the feeding tube.
Repeat Step 5. Check that no pieces of tablet are left in the syringe. Repeat Step 5 until no pieces remain.
Note: If according to the prescription the dose is more than 2 tablets, repeat Steps 1 through 5 until the full dose is received. You can use the same syringe.

If you have accidentally taken a higher dose

If you have taken an overdose, or if a child has accidentally swallowed some medicine, immediately see a doctor or go to a hospital emergency room and bring the medicine package with you.

If you forget to take the medicine at the scheduled time

Do not take a double dose. Take the next dose at the usual time and consult your doctor.

Adhere to the treatment as recommended by your doctor.
Even if your health improves, do not stop taking this medicine without consulting your doctor.

Do not take medicines in the dark! Check the label and dose every time you take medicine. Wear glasses if you need them.
If you have any further questions about using this medicine, consult your doctor or pharmacist.

4. Side effects

As with any medicine, using Livtencity may cause side effects in some users. Do not be alarmed by this list of side effects; you may not experience any of them.

Very common side effects - affect more than one in ten users:

- changes in taste
- nausea
- diarrhea
- vomiting
- tiredness

Additional side effects:

- acute kidney injury
- disease relapse due to resistance to treatment
- decreased white blood cell (neutrophils) level
- decreased hemoglobin level in the blood
- decreased blood platelet level
- increased creatinine level

If you experience any side effect, if any side effect gets worse, or if you experience a side effect not mentioned in this leaflet, consult your doctor.

Reporting side effects
You can report side effects to the Ministry of Health by following the 'Reporting Side Effects of Drug Treatment' link on the Ministry of Health home page (www.health.gov.il), which opens an online form for reporting side effects, or you can also use this link: https://sideeffects.health.gov.il

5. How to store the medicine?

- Prevent poisoning! To prevent poisoning, keep this and all other medicines in a closed place, out of the reach and sight of children and/or infants. Do not induce vomiting unless explicitly instructed to do so by the doctor.
- Do not use the medicine after the expiry date (exp. date) which is stated on the package. The expiry date refers to the last day of that month.
- **Storage conditions**
  Do not store above 30°C.
- Do not throw away medicines via wastewater or household waste. Ask the pharmacist how to dispose of medicines you no longer use. These measures will help protect the environment.

6. Additional information

In addition to the active ingredient, this medicine also contains:

Tablet core:
Microcrystalline cellulose, sodium starch glycolate, magnesium stearate.
Tablet coating:
Polyvinyl alcohol, macrogol/polyethylene glycol, titanium dioxide, talc, FD&C Blue #1.

What the medicine looks like and contents of the pack:

A blue, oval film-coated tablet with beveled edges, with 'SHP' printed on one side and '620' on the other side.
The tablets are packed in a bottle containing 28 or 56 tablets with a child-resistant cap.
Not all pack sizes may be marketed.

Registration holder's name and address: Takeda Israel Ltd., 25 Efal St., P.O.B 4140, Petach Tikva 4951125, Israel.

Manufacturer's name and address:

Takeda Ireland Ltd., Bray Business Park, Kilruddery, Co. Wicklow, A98 CD36, Ireland

This leaflet was approved in August 2023.
Registration number of the medicine in the Ministry of Health National Drug Registry:
173-33-37360-99